Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership

May 05, 2017

LAVAL, Quebec, May 5, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced appointments to the dermatology leadership team of Michael McMyne, who has joined as vice president of Sales, and Stacey Williams, who has joined as vice president of Marketing. Additionally, the company announced Lainie Keller has joined as vice president of Corporate Communications.

New Leadership Team Members Bolster Valeant Dermatology

In his new role, McMyne will be responsible for the dermatology sales force. He most recently served as vice president of operations for Merz North America, Inc., a specialty pharmaceutical and medical device company focused on dermatology, aesthetics medicine and neurosciences. While at Merz, Mr. McMyne launched a channel marketing team and led the integration of two key acquisitions into the company's dermatology portfolio. Prior to that, McMyne served in various commercial roles at Medicis Pharmaceuticals, including associate director of sales for dermatology.

Williams has joined Valeant to oversee the marketing strategy and execution of the dermatology organization. She has diverse experience in the commercial health care segment that includes medical devices, pharmaceuticals, R&D and manufacturing. Prior to this new role, she was senior marketing director for Merz North America, where she led strategic direction and tactical execution for a neuroscience portfolio that included biologic, pharmaceutical and medical device products.

"Michael and Stacey each have a proven track record of results, execution and strategic agility within specialty pharmaceuticals and more specifically, the specialty of dermatology," said Bill Humphries, executive vice president and company group chairman, Valeant Dermatology. We are committed to securing the company's future in the dermatology space, and I look forward to working with these talented leaders to realize the full potential of this key business for Valeant."

New Role Enhances Corporate Communications Capabilities

In a newly created role, Keller will be responsible for executing external corporate communications and media relations strategies for Valeant. She joined the company from Merck & Co., Inc., where she most recently served as a director of corporate media relations, overseeing corporate, financial, litigation and policy communications. During her 10 years at Merck, she also served as a director of communications for various product portfolios. Prior to that, she worked at various public relations firms for more than 10 years, managing business for health care, corporate and consumer clients.

"Communicating accurately and transparently is one of our highest priorities," said Scott Hirsch, senior vice president, Business Strategy and Communications, Valeant. "Lainie's experience in developing and leading successful, strategic communications programs on behalf of global

pharmaceutical and health care companies will be invaluable as we continue to transform Valeant."

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com

.

Forward-looking Statements

This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

Contact Information:

Investors:

Elif McDonald elif.mcdonald@valeant.com

514-856-3855 877-281-6642 (toll free)

Media:

Renée Soto or Chris Kittredge/Jared Levy Sard Verbinnen & Co. 212-687-8080

To view the original version on PR Newswire, visit:

http://www.prnewswire.com/news-releases/valeant-announces-key-appointments-in-dermatology-and-corporate-communications-leadership-300452636.html

SOURCE Valeant Pharmaceuticals International, Inc.





LEGAL NOTICE PRIVACY POLICY **Investor Inquiries**

<u>ir@bauschhealth.com</u>

877-281-6642 514-856-3855 (Canada) **EMAIL ALERTS** EMAIL PAGE **RSS FEED**

Media inquiries

<u>Corporate.communications@bauschhealth.com</u>

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.

©2025 Bausch Health Companies Inc. All rights

reserved. MTB.0230.USA.18 V2.0

908-569-3692

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

